DMAC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DiaMedica Therapeutics Inc (DMAC) is not a strong buy at the moment for a beginner investor with a long-term perspective. While the stock is oversold based on RSI and has a favorable analyst rating with a $14 price target, the lack of recent positive financial performance, absence of significant trading trends, and no active proprietary trading signals suggest holding off on investment until more favorable conditions arise.
The stock is oversold with an RSI of 19.202, indicating potential for a rebound. However, the MACD histogram is negative (-0.0783) and contracting, showing weak momentum. Moving averages are converging, and the stock is trading near its support level of 6.927, with resistance at 7.958.
Analyst rating from Lake Street highlights DMAC as a top idea with a $14 price target and potential for meaningful catalysts in the next 12-18 months.
No recent news or significant trading trends from hedge funds, insiders, or Congress. Financial performance is poor, with no revenue, net income, or EPS growth in the latest quarter.
In Q3 2025, the company reported zero revenue, net income, and EPS, showing no growth YoY. Gross margin also remained at zero.
Lake Street maintains a Buy rating with a $14 price target, citing potential catalysts over the next 12-18 months.
